Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736)

(2017) B. I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

(2010) Manuela Schmidinger et al.   CANCER TREATMENT REVIEWS

Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers

(2010) A Lindauer et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer

(2010) K.D. Steffensen et al.   GYNECOLOGIC ONCOLOGY

Reply to B.I. Rini et al

(2010) Darren R. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Toxicity of Sunitinib Plus Bevacizumab in Renal Cell Carcinoma

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGF Polymorphisms are Associated With an Increasing Risk of Developing Renal Cell Carcinoma

(2010) Franck Bruyère et al.   JOURNAL OF UROLOGY

Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors

(2010) Susan A. J. Vaziri et al.   Current Oncology Reports

VEGF kinase inhibitors: how do they cause hypertension?

(2009) Pankaj Bhargava   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

(2009) Brett E. Houk et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer

(2009) B. P. Schneider et al.   CLINICAL CANCER RESEARCH

Impact of anti-angiogenic treatments on metastatic renal cell carcinoma

(2009) Nicola L Ainsworth et al.   Expert Review of Anticancer Therapy

Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

(2009) Carie S. Facemire et al.   HYPERTENSION

Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma

(2009) Darren R. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

(2009) Nielka P. van Erp et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors

(2009) L. Jain et al.   MOLECULAR CANCER THERAPEUTICS

Adverse effects of anticancer agents that target the VEGF pathway

(2009) Helen X. Chen et al.   Nature Reviews Clinical Oncology

Vascular Endothelial Growth Factor Genotypes, Haplotypes, Gender, and the Risk of Non-Small Cell Lung Cancer

(2008) R. Zhai et al.   CLINICAL CANCER RESEARCH

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma

(2008) Toni K. Choueiri et al.   JOURNAL OF UROLOGY